These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 18499335

  • 21. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S, Kuroiwa K, Kinukawa N, Goto K, Koga H, Ogawa O, Murai M, Shiraishi T, Clinicopathological Research Group for Localized Prostate Cancer Investigators.
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [Abstract] [Full Text] [Related]

  • 22. Improved accuracy for predicting the Gleason score of prostate cancer by increasing the number of transrectal biopsy cores.
    Miyake H, Kurahashi T, Takenaka A, Hara I, Fujisawa M.
    Urol Int; 2007 Sep; 79(4):302-6. PubMed ID: 18025846
    [Abstract] [Full Text] [Related]

  • 23. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
    Tareen B, Godoy G, Sankin A, Temkin S, Lepor H, Taneja SS.
    BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784
    [Abstract] [Full Text] [Related]

  • 24. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men.
    Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ, Doo SH, Jeong SJ, Yoon CY, Byun SS, Choe G, Hwang SI, Lee HJ, Hong SK.
    BJU Int; 2010 Jun; 105(11):1526-30. PubMed ID: 19912202
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
    Dong F, Kattan MW, Steyerberg EW, Jones JS, Stephenson AJ, Schröder FH, Klein EA.
    J Urol; 2008 Jul; 180(1):150-4; discussion 154. PubMed ID: 18485398
    [Abstract] [Full Text] [Related]

  • 29. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE, Shikanov S, Katz MH, Gofrit ON, Eggener S, Zagaja GP, Shalhav AL, Zorn KC.
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [Abstract] [Full Text] [Related]

  • 30. Extended 12-core prostate biopsy increases both the detection of prostate cancer and the accuracy of Gleason score.
    Elabbady AA, Khedr MM.
    Eur Urol; 2006 Jan; 49(1):49-53; discussion 53. PubMed ID: 16314035
    [Abstract] [Full Text] [Related]

  • 31. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK.
    Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
    [Abstract] [Full Text] [Related]

  • 32. Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years.
    Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ, Soloway MS.
    Urology; 2008 Jul; 72(1):177-82. PubMed ID: 18279938
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Comparison of cancers detected at only a sextant or alternative location.
    Ochiai A, Troncoso P, Babaian RJ.
    BJU Int; 2008 Apr; 101(7):837-40. PubMed ID: 18070187
    [Abstract] [Full Text] [Related]

  • 35. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N, Lane BR, Li J, Moussa AS, Soriano M, Jones JS.
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [Abstract] [Full Text] [Related]

  • 36. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
    Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, Salomon L, Allory Y, Vordos D, Hoznek A, Yiou R, Patard JJ, Abbou CC, de la Taille A.
    Eur Urol; 2009 Mar; 55(3):600-6. PubMed ID: 18597923
    [Abstract] [Full Text] [Related]

  • 37. Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study.
    Haese A, Chaudhari M, Miller MC, Epstein JI, Huland H, Palisaar J, Graefen M, Hammerer P, Poole EC, O'Dowd GJ, Partin AW, Veltri RW.
    Cancer; 2003 Feb 15; 97(4):969-78. PubMed ID: 12569595
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study.
    Kvåle R, Møller B, Wahlqvist R, Fosså SD, Berner A, Busch C, Kyrdalen AE, Svindland A, Viset T, Halvorsen OJ.
    BJU Int; 2009 Jun 15; 103(12):1647-54. PubMed ID: 19154461
    [Abstract] [Full Text] [Related]

  • 40. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
    Loeb S, Sutherland DE, D'Amico AV, Roehl KA, Catalona WJ.
    Urology; 2008 Nov 15; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.